Skip to main
SLNO

Soleno Therapeutics (SLNO) Stock Forecast & Price Target

Soleno Therapeutics (SLNO) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 11%
Buy 56%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Soleno Therapeutics Inc. has demonstrated a positive financial trajectory with preliminary unaudited net revenues for full-year 2025 estimated at $190 million, including a robust $92 million generated in the fourth quarter alone. The company's strong product adoption and market access are reflected in the receipt of 1,250 total new patient start forms, indicating approximately 12.5% penetration into the addressable U.S. market for VYKAT XR. Additionally, Soleno maintains a solid cash position projected at around $500 million by the end of 2025, which supports its strategic initiatives for mergers and acquisitions or licensing opportunities.

Bears say

Soleno Therapeutics Inc faces a negative outlook primarily due to challenges related to market access and reimbursement issues impacting the uptake of its DCCR product. Furthermore, there are concerns regarding the potential for earlier-than-expected generic competition that could erode the DCCR franchise, coupled with the company’s difficulties in optimizing the value of DCCR in international markets. Additionally, risks surrounding slower-than-anticipated U.S. market performance further exacerbate the company's financial position, leading to a reconsideration of its stock valuation.

Soleno Therapeutics (SLNO) has been analyzed by 9 analysts, with a consensus rating of Buy. 11% of analysts recommend a Strong Buy, 56% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Soleno Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Soleno Therapeutics (SLNO) Forecast

Analysts have given Soleno Therapeutics (SLNO) a Buy based on their latest research and market trends.

According to 9 analysts, Soleno Therapeutics (SLNO) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Soleno Therapeutics (SLNO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.